xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06033547</url>
    </required_header>
    <id_info>
      <org_study_id>219406</org_study_id>
      <nct_id>NCT06033547</nct_id>
    </id_info>
    <brief_title>A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants</brief_title>
    <official_title>A Phase I, Open-label, Single Dose Escalation Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Two Different Formulations of Long-acting Cabotegravir Administered to Healthy Adult Participants</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>ViiV Healthcare</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>ViiV Healthcare</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
      <is_us_export>No</is_us_export>
    </oversight_info>
    <brief_summary>
      <textblock>
        The primary purpose of the study is to investigate the safety, tolerability, and&#xD;
        pharmacokinetic (PK) profiles of two different cabotegravir formulations in healthy adult&#xD;
        participants. The study will initially start with the assessment of Cabotegravir Formulation&#xD;
        F. Once the clinical batch of Cabotegravir Formulation G is available and depending on data&#xD;
        for Formulation F, this formulation will be assessed.&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 11, 2023</start_date>
    <completion_date type="Anticipated">February 19, 2025</completion_date>
    <primary_completion_date type="Anticipated">February 19, 2025</primary_completion_date>
    <phase>Phase 1</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>Yes</has_expanded_access>
    <study_design_info>
      <allocation>Non-Randomized</allocation>
      <intervention_model>Sequential Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Maximum observed plasma concentration (Cmax) of cabotegravir</measure>
      <time_frame>Up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Time of maximum observed plasma concentration (tmax) of cabotegravir</measure>
      <time_frame>Up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Area under the concentration - time curve from time zero to 4 weeks following the injection (AUC[0-4]) of cabotegravir</measure>
      <time_frame>Up to Week 4</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Plasma Concentration of cabotegravir at Week 4</measure>
      <time_frame>Week 4</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Number of participants with adverse events (AEs) based on severity</measure>
      <time_frame>Up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Absolute value of haematology parameter: Platelet count (cells per microliter)</measure>
      <time_frame>Up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Absolute value of haematology parameter: Red Blood Cell Count (RBC) (million cells per microliter)</measure>
      <time_frame>Up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Absolute values of haematology parameters: haemoglobin (Hgb) (grams per decilitre)</measure>
      <time_frame>Up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Absolute values of haematology parameters: haematocrit (Proportion of red blood cells in blood)</measure>
      <time_frame>Up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Absolute value of haematology parameter: Mean Corpuscle Volume (MCV) (Femtoliters)</measure>
      <time_frame>Up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Absolute value of haematology parameter: Mean Corpuscle haemoglobin (MCH) (Picograms)</measure>
      <time_frame>Up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Absolute values of haematology parameters: Reticulocytes (Percentage of reticulocytes)</measure>
      <time_frame>Up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Absolute values of haematology parameters: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per litre)</measure>
      <time_frame>Up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Absolute values of Clinical Chemistry parameters: Glucose (fasting), Blood Urea Nitrogen (BUN), Creatinine, Sodium, Potassium, Calcium, Direct Bilirubin and Total Bilirubin (milligrams per decilitre)</measure>
      <time_frame>Up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Absolute values of Clinical Chemistry parameters: AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per litre)</measure>
      <time_frame>Up to Week 52</time_frame>
      <description>Clinical chemistry parameters such as Aspartate Aminotransferase (AST) / Serum Glutamic-Oxaloacetic Transaminase (SGOT), Alanine Aminotransferase (ALT)/ Serum Glutamic-Pyruvic Transaminase and (SGPT), Alkaline phosphatase (ALP) and Creatinine Phosphokinase (CPK) will be analysed.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Absolute values of Clinical chemistry parameters: Total Protein (Grams per deciliter)</measure>
      <time_frame>Up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Absolute values of Clinical chemistry parameters: Estimated Glomerular Filtration Rate (eGFR2) (millilitres per minute)</measure>
      <time_frame>Up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Change from Baseline in haematology parameter: Platelet count (cells per microliter)</measure>
      <time_frame>Baseline (Day 1) and up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Change from Baseline in haematology parameter: Red Blood Cell Count (RBC) (million cells per microliter)</measure>
      <time_frame>Baseline (Day 1) and up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Change from baseline in haematology parameters: haematocrit (Proportion of red blood cells in blood)</measure>
      <time_frame>Baseline (Day 1) and up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Change from baseline in haematology parameter: Mean Corpuscle Volume (MCV) (Femtoliters)</measure>
      <time_frame>Baseline (Day 1) and up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Change from baseline in haematology parameter: Mean Corpuscle haemoglobin (MCH) (Picograms)</measure>
      <time_frame>Baseline (Day 1) and up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Change from baseline in haematology parameters: Reticulocytes (Percentage of reticulocytes)</measure>
      <time_frame>Baseline (Day 1) and up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Change from baseline in haematology parameters: Differential count of Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per litre)</measure>
      <time_frame>Baseline (Day 1) and up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Change from baseline in Clinical Chemistry parameters: Glucose (fasting), Blood Urea Nitrogen (BUN), Creatinine, Sodium, Potassium, Calcium, Direct Bilirubin and Total Bilirubin (milligrams per decilitre)</measure>
      <time_frame>Baseline (Day 1) and up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Change from baseline in Clinical Chemistry parameters: AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per litre)</measure>
      <time_frame>Baseline (Day 1) and up to Week 52</time_frame>
      <description>Clinical chemistry parameters such as Aspartate Aminotransferase (AST) / Serum Glutamic-Oxaloacetic Transaminase (SGOT), Alanine Aminotransferase (ALT)/ Serum Glutamic-Pyruvic Transaminase and (SGPT), Alkaline phosphatase (ALP) and Creatinine Phosphokinase (CPK) will be analysed</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Change from baseline in Clinical chemistry parameters: Total Protein (Grams per deciliter)</measure>
      <time_frame>Baseline (Day 1) and up to Week 52</time_frame>
    </primary_outcome>
    <primary_outcome>
      <measure>Change from baseline in Clinical chemistry parameters: Estimated Glomerular Filtration Rate (eGFR) (millilitres per minute)</measure>
      <time_frame>Baseline (Day 1) and up to Week 52</time_frame>
    </primary_outcome>
    <secondary_outcome>
      <measure>Area under the concentration - time curve from time zero to infinity (AUC[0-inf]) of cabotegravir</measure>
      <time_frame>Up to Week 52</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Area under the concentration - time curve from time zero to time of last quantifiable concentration [AUC(0-last)] of cabotegravir</measure>
      <time_frame>Up to Week 52</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Plasma Concentration of cabotegravir at Week 8,12 and 24</measure>
      <time_frame>Week 8, 12 and 24</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Apparent terminal phase half-life (t1/2) of cabotegravir</measure>
      <time_frame>Up to Week 52</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Apparent long-acting absorption rate constant (KA-LA) of cabotegravir</measure>
      <time_frame>Up to Week 52</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Dose proportionality of cabotegravir based on AUC(0-inf), AUC(0-last), Cmax, and plasma concentration (Unit of measure: Slope of log dose)</measure>
      <time_frame>Up to Week 52</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Number of participants with maximum post-baseline QTc values compared to baseline by category (to &lt;=450 milliseconds (msec) or no change, to &gt;450 msec to &lt;=480 msec, to &gt;480 msec to &lt;=500 msec, and to &gt;500 msec)</measure>
      <time_frame>Up to Week 52</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Number of participants with maximum post-baseline increase in QTc values compared to baseline based on category (increase &lt;=30 msec, increase of 31-60 msec, and increase of &gt;60 msec)</measure>
      <time_frame>Up to Week 52</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Number of participants with worst case post-baseline values relative to potential clinical importance criteria compared to baseline for diastolic blood pressure (DBP), systolic blood pressure (SBP) and pulse rate</measure>
      <time_frame>Up to Week 52</time_frame>
      <description>Number of participants with worst case post-baseline values relative to potential clinical importance criteria compared to baseline will be categorized into change to low, change to within range or no change, and change to high</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">48</enrollment>
    <condition>HIV Infections</condition>
    <arm_group>
      <arm_group_label>Part A: Participants receiving Cabotegravir Formulation F</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
    </arm_group>
    <arm_group>
      <arm_group_label>Part B: Participants receiving Cabotegravir Formulation G</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Cabotegravir Formulation F</intervention_name>
      <description>Cabotegravir Formulation F will be administered</description>
      <arm_group_label>Part A: Participants receiving Cabotegravir Formulation F</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Cabotegravir Formulation G</intervention_name>
      <description>Cabotegravir Formulation G will be administered</description>
      <arm_group_label>Part B: Participants receiving Cabotegravir Formulation G</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Participants who are overtly healthy as determined by medical evaluation including&#xD;
               medical history, physical examination, laboratory tests, and cardiac monitoring&#xD;
  &#xD;
            -  Body weight =&gt;40 kilogram (kg) and body mass index (BMI) within the range =&gt;18 to =&lt;32&#xD;
               kilogram per meter square (kg/m^2)&#xD;
  &#xD;
            -  Participants who are negative on a single test for Severe acute respiratory syndrome&#xD;
               coronavirus 2 (SARS-CoV-2)(approved molecular polymerase chain reaction [PCR]&#xD;
               laboratory or point of care test) performed on the day of admission. A negative result&#xD;
               is required prior to the administration of study intervention on Day 1.&#xD;
  &#xD;
            -  Contraceptive use by men and women should be consistent with local regulations&#xD;
               regarding the methods of contraception for those participating in clinical studies&#xD;
  &#xD;
            -  Participants assigned female at birth are eligible to participate if they are not&#xD;
               pregnant or breastfeeding, and at least one of the following conditions applies:&#xD;
  &#xD;
            -  Is not a woman of childbearing potential (WOCBP) OR&#xD;
  &#xD;
            -  Is a WOCBP and using a contraceptive method that is highly effective, with a failure&#xD;
               rate of &lt;1% from the time of screening and inclusive of the entire time while on the&#xD;
               study.&#xD;
  &#xD;
            -  A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as&#xD;
               required by local regulations) within the 30 days before the first dose of study&#xD;
               intervention.&#xD;
  &#xD;
            -  Capable of giving written informed consent&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Current presence or history of cardiovascular, respiratory, hepatic, renal,&#xD;
               gastrointestinal, endocrine, haematological, or neurological disorders.&#xD;
  &#xD;
            -  Current or chronic history of liver disease or known hepatic or biliary abnormalities.&#xD;
  &#xD;
            -  History of ongoing or clinically relevant seizure disorder within the previous 2&#xD;
               years, including participants who have required treatment for seizures within this&#xD;
               time period.&#xD;
  &#xD;
            -  Participants who in the investigator's judgment, poses a significant suicidality risk.&#xD;
               Participant's history of suicidal behavior and/or suicidal ideation should be&#xD;
               considered when evaluating for suicide risk.&#xD;
  &#xD;
            -  Signs and symptoms which, in the opinion of the investigator, are suggestive of&#xD;
               coronavirus disease 2019 (COVID-19) (e.g., fever, cough) within 14 days prior to&#xD;
               screening; and/or contact with known COVID-19 positive person(s) in the 14 days prior&#xD;
               to screening.&#xD;
  &#xD;
            -  Human immunodeficiency virus (HIV-1 or HIV-2) infection as indicated by positive&#xD;
               antibody/antigen test.&#xD;
  &#xD;
            -  History of or on-going high-risk behaviors that, in the opinion of the investigator,&#xD;
               may put the participant at increased risk for HIV infection including, but not limited&#xD;
               to, participants in HIV discordant relationships, or men who report current or prior&#xD;
               unprotected anal sex with other men and those reporting prior or current injecting&#xD;
               drug use.&#xD;
  &#xD;
            -  Presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C antibody test&#xD;
               result at screening or within 3 months prior to first dose of study treatment.&#xD;
  &#xD;
            -  Abnormal blood pressure.&#xD;
  &#xD;
            -  Evidence of previous myocardial infarction.&#xD;
  &#xD;
            -  Any conduction abnormality (including but not specific to left or right complete&#xD;
               bundle branch block, atrioventricular [AV] block [2nd degree or higher], Wolff-&#xD;
               Parkinson-White [WPW] syndrome).&#xD;
  &#xD;
            -  Any significant arrhythmia which, in the opinion of the investigator or the medical&#xD;
               monitor, will interfere with the safety for the individual participant.&#xD;
  &#xD;
            -  One or more exclusionary values for a screening Electrocardiogram (ECG).&#xD;
  &#xD;
            -  Alanine transaminase (ALT) &gt;1.5x upper limit of normal (ULN).&#xD;
  &#xD;
            -  Bilirubin &gt;1.5xULN (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is&#xD;
               fractionated and direct bilirubin &lt;35 percent [%]).&#xD;
  &#xD;
            -  Estimated Glomerular Filtration Rate (eGFR) &lt;60 milliliter per minute (mL/min) using&#xD;
               the Chronic Kidney Disease - Improved Prediction Equations (CKD-EPI) Creatinine&#xD;
               Equation (2021).&#xD;
  &#xD;
            -  Haemoglobin &lt;12.5 gram per deciliter (g/dL) for men and &lt;11 g/dL for women.&#xD;
  &#xD;
            -  Positive pre-study drug/alcohol screen.&#xD;
  &#xD;
            -  Regular use of tobacco- or nicotine-containing products within 3 months prior to&#xD;
               screening; or urinary cotinine levels indicative of smoking or history or regular use&#xD;
               of tobacco- or nicotine-containing products (e.g., nicotine patches or vaporizing&#xD;
               devices).&#xD;
  &#xD;
            -  Regular alcohol consumption within 6 months prior to the study defined as an average&#xD;
               weekly intake of &gt;14 units for males or &gt;7 units for females.&#xD;
  &#xD;
            -  Regular use of known drugs of abuse.&#xD;
  &#xD;
            -  Concurrent participation in another clinical trial (except imaging trials); or has&#xD;
               participated in a clinical trial and received an investigational product within the&#xD;
               following time period prior to the first dosing day in this study: 30 days, 5&#xD;
               half-lives or twice the duration of the biological effect of the investigational&#xD;
               product (whichever is longer).&#xD;
  &#xD;
            -  Participation in the study would result in loss of blood or blood products in excess&#xD;
               of 500 mL within 56 days.&#xD;
  &#xD;
            -  Exposure to more than four (4) new chemical entities within 12 months prior to the&#xD;
               first dosing day.&#xD;
  &#xD;
            -  History of sensitivity to any of the study interventions (or components thereof), a&#xD;
               history of drug allergy or other allergy that, in the opinion of the investigator or&#xD;
               medical monitor, contraindicates their participation&#xD;
  &#xD;
            -  Current or anticipated need for chronic anti-coagulation therapy (with the exception&#xD;
               of low-dose aspirin =&lt; 325 mg/day)&#xD;
  &#xD;
            -  Hereditary coagulation and platelet disorders (e.g., haemophilia or Von Willebrand&#xD;
               disease [VWD]).&#xD;
  &#xD;
            -  Participant has a tattoo overlying the location of injection or an underlying skin&#xD;
               disease or condition (e.g., infection, inflammation, dermatitis, eczema, drug rash,&#xD;
               drug allergy, psoriasis, food allergy, urticaria) that, in the opinion of the&#xD;
               investigator, may interfere with interpretation of injection site reactions or&#xD;
               administration of study intervention.&#xD;
  &#xD;
            -  Any other clinical condition, behaviour or prior therapy that, in the opinion of the&#xD;
               investigator, would make the participant unsuitable for the study; unable to comply&#xD;
               with dosing requirements; or unable to comply with study visits.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>55 Years</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <overall_contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 89904466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>GSK Investigational Site</name>
        <address>
          <city>Austin</city>
          <state>Texas</state>
          <zip>78744</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>US GSK Clinical Trials Call Center</last_name>
        <phone>877-379-3718</phone>
        <email>GSKClinicalSupportHD@gsk.com</email>
      </contact>
      <contact_backup>
        <last_name>EU GSK Clinical Trials Call Centre</last_name>
        <phone>+44 (0) 20 8990 4466</phone>
        <email>GSKClinicalSupportHD@gsk.com</email>
      </contact_backup>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <verification_date>September 2023</verification_date>
    <study_first_submitted>August 31, 2023</study_first_submitted>
    <study_first_submitted_qc>September 4, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 13, 2023</study_first_posted>
    <last_update_submitted>September 4, 2023</last_update_submitted>
    <last_update_submitted_qc>September 4, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 13, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Cabotegravir</keyword>
    <keyword>Pharmacokinetics</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>HIV Infections</mesh_term>
    </condition_browse>
    <intervention_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Cabotegravir</mesh_term>
    </intervention_browse>
    <patient_data>
      <sharing_ipd>Yes</sharing_ipd>
      <ipd_description>Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/</ipd_description>
      <ipd_info_type>Study Protocol</ipd_info_type>
      <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
      <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
      <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
      <ipd_time_frame>Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.</ipd_time_frame>
      <ipd_access_criteria>Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.</ipd_access_criteria>
      <ipd_url>https://www.gsk.com/en-gb/innovation/trials/data-transparency/</ipd_url>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06033547
  org study id: 219406
  nct id: NCT06033547
  lead sponsor: 
  has dmc: Yes
  is fda regulated drug: Yes
  is fda regulated device: No
  is us export: No
  The primary purpose of the study is to investigate the safety, tolerability, and
        pharmacokinetic (PK) profiles of two different cabotegravir formulations in healthy adult
        participants. The study will initially start with the assessment of Cabotegravir Formulation
        F. Once the clinical batch of Cabotegravir Formulation G is available and depending on data
        for Formulation F, this formulation will be assessed.
  allocation: Non-Randomized
  intervention model: Sequential Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Maximum observed plasma concentration (Cmax) of cabotegravir
  time frame: Up to Week 52
  measure: Time of maximum observed plasma concentration (tmax) of cabotegravir
  time frame: Up to Week 52
  measure: Area under the concentration - time curve from time zero to 4 weeks following the injection (AUC[0-4]) of cabotegravir
  time frame: Up to Week 4
  measure: Plasma Concentration of cabotegravir at Week 4
  time frame: Week 4
  measure: Number of participants with adverse events (AEs) based on severity
  time frame: Up to Week 52
  measure: Absolute value of haematology parameter: Platelet count (cells per microliter)
  time frame: Up to Week 52
  measure: Absolute value of haematology parameter: Red Blood Cell Count (RBC) (million cells per microliter)
  time frame: Up to Week 52
  measure: Absolute values of haematology parameters: haemoglobin (Hgb) (grams per decilitre)
  time frame: Up to Week 52
  measure: Absolute values of haematology parameters: haematocrit (Proportion of red blood cells in blood)
  time frame: Up to Week 52
  measure: Absolute value of haematology parameter: Mean Corpuscle Volume (MCV) (Femtoliters)
  time frame: Up to Week 52
  measure: Absolute value of haematology parameter: Mean Corpuscle haemoglobin (MCH) (Picograms)
  time frame: Up to Week 52
  measure: Absolute values of haematology parameters: Reticulocytes (Percentage of reticulocytes)
  time frame: Up to Week 52
  measure: Absolute values of haematology parameters: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per litre)
  time frame: Up to Week 52
  measure: Absolute values of Clinical Chemistry parameters: Glucose (fasting), Blood Urea Nitrogen (BUN), Creatinine, Sodium, Potassium, Calcium, Direct Bilirubin and Total Bilirubin (milligrams per decilitre)
  time frame: Up to Week 52
  measure: Absolute values of Clinical Chemistry parameters: AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per litre)
  time frame: Up to Week 52
  description: Clinical chemistry parameters such as Aspartate Aminotransferase (AST) / Serum Glutamic-Oxaloacetic Transaminase (SGOT), Alanine Aminotransferase (ALT)/ Serum Glutamic-Pyruvic Transaminase and (SGPT), Alkaline phosphatase (ALP) and Creatinine Phosphokinase (CPK) will be analysed.
  measure: Absolute values of Clinical chemistry parameters: Total Protein (Grams per deciliter)
  time frame: Up to Week 52
  measure: Absolute values of Clinical chemistry parameters: Estimated Glomerular Filtration Rate (eGFR2) (millilitres per minute)
  time frame: Up to Week 52
  measure: Change from Baseline in haematology parameter: Platelet count (cells per microliter)
  time frame: Baseline (Day 1) and up to Week 52
  measure: Change from Baseline in haematology parameter: Red Blood Cell Count (RBC) (million cells per microliter)
  time frame: Baseline (Day 1) and up to Week 52
  measure: Change from baseline in haematology parameters: haematocrit (Proportion of red blood cells in blood)
  time frame: Baseline (Day 1) and up to Week 52
  measure: Change from baseline in haematology parameter: Mean Corpuscle Volume (MCV) (Femtoliters)
  time frame: Baseline (Day 1) and up to Week 52
  measure: Change from baseline in haematology parameter: Mean Corpuscle haemoglobin (MCH) (Picograms)
  time frame: Baseline (Day 1) and up to Week 52
  measure: Change from baseline in haematology parameters: Reticulocytes (Percentage of reticulocytes)
  time frame: Baseline (Day 1) and up to Week 52
  measure: Change from baseline in haematology parameters: Differential count of Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per litre)
  time frame: Baseline (Day 1) and up to Week 52
  measure: Change from baseline in Clinical Chemistry parameters: Glucose (fasting), Blood Urea Nitrogen (BUN), Creatinine, Sodium, Potassium, Calcium, Direct Bilirubin and Total Bilirubin (milligrams per decilitre)
  time frame: Baseline (Day 1) and up to Week 52
  measure: Change from baseline in Clinical Chemistry parameters: AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per litre)
  time frame: Baseline (Day 1) and up to Week 52
  description: Clinical chemistry parameters such as Aspartate Aminotransferase (AST) / Serum Glutamic-Oxaloacetic Transaminase (SGOT), Alanine Aminotransferase (ALT)/ Serum Glutamic-Pyruvic Transaminase and (SGPT), Alkaline phosphatase (ALP) and Creatinine Phosphokinase (CPK) will be analysed
  measure: Change from baseline in Clinical chemistry parameters: Total Protein (Grams per deciliter)
  time frame: Baseline (Day 1) and up to Week 52
  measure: Change from baseline in Clinical chemistry parameters: Estimated Glomerular Filtration Rate (eGFR) (millilitres per minute)
  time frame: Baseline (Day 1) and up to Week 52
  measure: Area under the concentration - time curve from time zero to infinity (AUC[0-inf]) of cabotegravir
  time frame: Up to Week 52
  measure: Area under the concentration - time curve from time zero to time of last quantifiable concentration [AUC(0-last)] of cabotegravir
  time frame: Up to Week 52
  measure: Plasma Concentration of cabotegravir at Week 8,12 and 24
  time frame: Week 8, 12 and 24
  measure: Apparent terminal phase half-life (t1/2) of cabotegravir
  time frame: Up to Week 52
  measure: Apparent long-acting absorption rate constant (KA-LA) of cabotegravir
  time frame: Up to Week 52
  measure: Dose proportionality of cabotegravir based on AUC(0-inf), AUC(0-last), Cmax, and plasma concentration (Unit of measure: Slope of log dose)
  time frame: Up to Week 52
  measure: Number of participants with maximum post-baseline QTc values compared to baseline by category (to <=450 milliseconds (msec) or no change, to >450 msec to <=480 msec, to >480 msec to <=500 msec, and to >500 msec)
  time frame: Up to Week 52
  measure: Number of participants with maximum post-baseline increase in QTc values compared to baseline based on category (increase <=30 msec, increase of 31-60 msec, and increase of >60 msec)
  time frame: Up to Week 52
  measure: Number of participants with worst case post-baseline values relative to potential clinical importance criteria compared to baseline for diastolic blood pressure (DBP), systolic blood pressure (SBP) and pulse rate
  time frame: Up to Week 52
  description: Number of participants with worst case post-baseline values relative to potential clinical importance criteria compared to baseline will be categorized into change to low, change to within range or no change, and change to high
  arm group label: Part A: Participants receiving Cabotegravir Formulation F
  arm group type: Experimental
  arm group label: Part B: Participants receiving Cabotegravir Formulation G
  arm group type: Experimental
  intervention type: Drug
  intervention name: Cabotegravir Formulation F
  description: Cabotegravir Formulation F will be administered
  arm group label: Part A: Participants receiving Cabotegravir Formulation F
  intervention type: Drug
  intervention name: Cabotegravir Formulation G
  description: Cabotegravir Formulation G will be administered
  arm group label: Part B: Participants receiving Cabotegravir Formulation G
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 55 Years
  healthy volunteers: Accepts Healthy Volunteers
  last name: US GSK Clinical Trials Call Center
  phone: 877-379-3718
  email: GSKClinicalSupportHD@gsk.com
  last name: EU GSK Clinical Trials Call Center
  phone: +44 (0) 20 89904466
  email: GSKClinicalSupportHD@gsk.com
  facility: 
  contact: 
  contact backup: 
  country: United States
  responsible party type: Sponsor
  mesh term: HIV Infections
  mesh term: Cabotegravir
  sharing ipd: Yes
  ipd description: Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
  ipd info type: Study Protocol
  ipd info type: Statistical Analysis Plan (SAP)
  ipd info type: Informed Consent Form (ICF)
  ipd info type: Clinical Study Report (CSR)
  ipd time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
  ipd access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
  ipd url: https://www.gsk.com/en-gb/innovation/trials/data-transparency/